NPO Petrovax Pharm’s concept is based on delivering original products. The company has an
The company holds more than 20 world patents for molecules, inventions, and pharmaceutical manufacturing processes.
The R&D Department structure provides for managing the molecule inception and product lifecycle from the idea to implementation in medical practice. Ad hoc studies are conducted with participation of leading domestic and foreign research institutions.
Innovative search for promising candidate molecules with subsequent assessment of their safety and specific activity
Studying mechanisms of action of development products in disease process
Safety profile and efficacy assay of a pharmaceutical
Development of quality control methods, and manufacturing processes
Planning and conducting pivotal clinical studies
Implementation of technological processes; upgrading and optimization of current processes; and production scaling
Presently, there are more than ten innovative products at different development stages in the company’s pipeline.
In the coming years, NPO Petrovax Pharm plans to launch to the market a new polymer combined medication to treat intoxication caused by different factors as well as three sustained release biopharmaceuticals with improved pharmacological properties based on recombinant therapeutic proteins to treat hepatitis B and C, anemia in chronic renal failure and cancer patients, and rheumatoid arthritis.
A quadrivalent adjuvant influenza vaccine effectively protecting against four influenza virus strains, with maximum safety profile, will be available on the market in 2018.